Dexcom Inc.

Dexcom Inc. is a leading medical technology company specializing in the development, manufacturing, and marketing of continuous glucose monitoring (CGM) systems. Its core products are designed to provide real-time glucose measurement for individuals with diabetes, enabling improved disease management and reducing the need for traditional fingerstick testing. Dexcom’s CGM solutions, such as the Stello CGM and the 15-day Com G7 system, play a pivotal role in both Type 1 and Type 2 diabetes care, supporting patients, healthcare providers, and caregivers in tracking glucose trends and making timely treatment decisions. Operating within the medical equipment, supplies, and distribution sector, Dexcom has achieved consistent revenue growth, driven by strong U.S. and international demand. Its business model emphasizes technological innovation, product reliability, and expanding access to advanced diabetes management tools. Dexcom’s financial performance reflects its market significance, with robust profitability, high gross margins, and a substantial global footprint. As a prominent player in the diabetes care industry, Dexcom Inc. continues to shape the future of glucose monitoring and chronic disease management worldwide.